2024年中报 | 2023年年报 | 2023年中报 | 2022年年报 | 2022年中报 | |
---|---|---|---|---|---|
营业收入(元) | |||||
抗炎类(元) | 176,250,429.11 | - | 345,992,930.29 | - | 186,613,962.00 |
抗肿瘤类(元) | 11,508,623.40 | 27,569,577.98 | 15,048,791.28 | 29,823,813.18 | 17,390,994.45 |
心血管类(元) | 32,959,160.08 | 62,804,041.86 | 31,022,004.96 | 53,438,146.67 | 23,692,839.11 |
非甾体抗炎类(元) | - | 534,890,438.34 | - | 385,750,885.37 | - |
其他(元) | 21,148,742.52 | 37,761,816.17 | 13,694,854.05 | 45,898,923.69 | 12,678,363.58 |
营业成本(元) | |||||
抗炎类(元) | 127,163,609.65 | - | 218,400,071.12 | - | 143,923,040.69 |
抗肿瘤类(元) | 8,714,623.79 | 14,948,907.70 | 7,411,604.37 | 20,380,370.81 | 14,153,740.93 |
心血管类(元) | 7,567,770.89 | 13,222,787.74 | 7,827,347.07 | 9,389,801.49 | 4,897,587.97 |
非甾体抗炎类(元) | - | 346,539,487.60 | - | 311,521,283.82 | - |
其他(元) | 11,340,684.27 | 21,963,368.92 | 12,235,819.90 | 24,926,535.08 | 8,124,753.30 |
毛利(元) | |||||
抗炎类(元) | 49,086,819.46 | - | 127,592,859.17 | - | 42,690,921.31 |
抗肿瘤类(元) | 2,793,999.61 | 12,620,670.28 | 7,637,186.91 | 9,443,442.37 | 3,237,253.52 |
心血管类(元) | 25,391,389.19 | 49,581,254.12 | 23,194,657.89 | 44,048,345.18 | 18,795,251.14 |
非甾体抗炎类(元) | - | 188,350,950.74 | - | 74,229,601.55 | - |
其他(元) | 9,808,058.25 | 15,798,447.25 | 1,459,034.15 | 20,972,388.61 | 4,553,610.28 |
毛利率(%) | |||||
抗炎类(%) | 27.85 | - | 36.88 | - | 22.88 |
抗肿瘤类(%) | 24.28 | 45.78 | 50.75 | 31.66 | 18.61 |
心血管类(%) | 77.04 | 78.95 | 74.77 | 82.43 | 79.33 |
非甾体抗炎类(%) | - | 35.21 | - | 19.24 | - |
其他(%) | 46.38 | 41.84 | 10.65 | 45.69 | 35.92 |
收入构成(%) | |||||
抗炎类(%) | 72.87 | - | 85.27 | - | 77.63 |
抗肿瘤类(%) | 4.76 | 4.16 | 3.71 | 5.79 | 7.23 |
心血管类(%) | 13.63 | 9.47 | 7.65 | 10.38 | 9.86 |
非甾体抗炎类(%) | - | 80.67 | - | 74.92 | - |
其他(%) | 8.74 | 5.70 | 3.38 | 8.91 | 5.27 |
毛利构成(%) | |||||
抗炎类(%) | 56.37 | - | 79.80 | - | 61.62 |
抗肿瘤类(%) | 3.21 | 4.74 | 4.78 | 6.35 | 4.67 |
心血管类(%) | 29.16 | 18.61 | 14.51 | 29.62 | 27.13 |
非甾体抗炎类(%) | - | 70.72 | - | 49.92 | - |
其他(%) | 11.26 | 5.93 | 0.91 | 14.10 | 6.57 |